Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

Russell-Jones, D, Cuddihy, RM, Hanefeld, M, Kumar, A, González, JG, Chan, M, Wolka, AM, Boardman, MK and DURATION-4 Study Group, (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care, 35 (2). pp. 252-258.

Full text not available from this repository.

Abstract

To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes.

Item Type:	Article
Divisions :	Surrey research (other units)
Authors :	Name Email ORCID Russell-Jones, D davidrussell-jones@nhs.net Cuddihy, RM Hanefeld, M Kumar, A González, JG Chan, M Wolka, AM Boardman, MK DURATION-4 Study Group,
Date :	February 2012
DOI :	10.2337/dc11-1107
Uncontrolled Keywords :	Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Pyrazines, Thiazolidinediones, Treatment Outcome, Triazoles, Venoms
Depositing User :	Symplectic Elements
Date Deposited :	17 May 2017 09:39
Last Modified :	24 Jan 2020 17:22
URI:	http://epubs.surrey.ac.uk/id/eprint/824574

Actions (login required)

View Item

Downloads